Latest News
and Evidence
Get the latest news about Afirma and managing thyroid nodules
Article Types:
  • Publications
  • Interviews
  • Cancer Cytopathology – The Afirma Xpression Atlas for Thyroid Nodules and Thyroid Cancer Metastases: Insights to Inform Clinical Decision-Making from a Fine-Needle Aspiration Sample
  • ENDO Oral Data – Identification of Novel and Rare Receptor Tyrosine Kinase Fusions in Thyroid Fine Needle Aspirates

    (ENDO 2020 canceled due to COVID-19)
  • ENDO Data – Positive Predictive Value of TP53 Variants in Bethesda III/IV Thyroid Fine-Needle Aspirates

    (ENDO 2020 canceled due to COVID-19)
  • JCEM – Real World Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules (Cleveland Clinic)
  • Cancer Cytopathology – Performance of the Afirma Genomic Sequencing Classifier Versus Gene Expression Classifier: An Institutional Experience (Fox Chase)
  • Frontiers in Endocrinology – Afirma Xpression Atlas Clinical & Analytical Validation Study
  • Thyroid Journal – Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules
  • ASCO Data – New Afirma Data Shows Potential to Guide Targeted Treatment for Medullary Thyroid Cancer
  • Thyroid Journal – Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules (B&W)
  • Cancer Cytopathology – Extending expressed RNA genomics from surgical decision making for cytologically indeterminate thyroid nodules to targeting therapies for metastatic thyroid cancer
  • BMC Systems Biology – Identification of Hürthle Cell Cancers: Solving a Clinical Challenge with Genomic Sequencing and a Trio of Machine Learning Algorithms
  • ENDO Data – New Afirma Xpression Atlas Data Advances Genomic Understanding of Medullary Thyroid Cancer
  • Endocrine Practice – Statistical Comparison of Afirma GSC and Afirma GEC Outcomes in a Community Endocrine Surgical Practice: Early Findings (Memorial Healthcare)
  • ATA Data – Interview with Christian Nasr, MD: Performance of Afirma Genomic Sequencing Classifier: The Initial Cleveland Clinic Experience
  • ATA Data – Interview with Erik Alexander, MD: Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules
  • ATA Data – Interview with Jennifer A. Sipos, MD: Experience with the Genomic Sequencing Classifier in >100 Cytologically Indeterminate Thyroid Nodules
  • Interview with R. Mack Harrell, MD: Afirma GSC: Early Endocrine Surgery Practice Performance 8/2017-2/2018
  • Interview with Peter M. Sadow, MD, PhD: Detecting Expressed Variants and Fusions in RNASeq Data from Thyroid FNAs
  • Interview with Christian Nasr, MD: Independent Academic Medical Center Afirma GSC Experience
  • Interview with Joshua Babiarz, PhD: The Mutational Landscape of 774 Variants and 132 Fusions in 513 Genes Measured in Thyroid FNAs from a Multicenter Blinded Cohort

    March 2018
  • Interview with Michael Shanik, MD: Afirma Genomic Sequencing Classifier Experience Among the First 5478 Consecutive Samples

    March 2018
  • Interview with R. Mack Harrell, MD: Reduced Surgery through Afirma GEC: Impact to date and potential for the future

    May 2017
  • Interview with Brian Michael, MD: Six-year Clinical and Imaging Follow-up of an Office-based Gene Expression Classifier

    May 2017
  • Interview with Whitney Goldner, MD: Institutional Experience with Afirma GEC after Repeat Biopsy

    April 2017
  • Interview with Matthew J. Levine, MD, FACE: Five Year Experience with Afirma Gene Expression Classifier (GEC)

    September 2016
  • Interview with Jennifer A. Sipos, MD: Long-Term Follow-Up of Afirma GEC Benign Results

    September 2016
  • Interview with Ying Hu, MD, PhD: More Incidental Thyroid Malignancies Observed in the Lobes with a GEC Suspicious Nodule

    September 2016
  • UCLA Study Evaluates Whether Afirma GEC Has Refined the Indeterminate Cytology Category

    May 2016
  • New Multicenter Long-term Outcome Study Demonstrates Durable Afirma GEC Benign Results

    March 2016
  • New Long-Term Follow-Up Study Demonstrates that Afirma GEC Benign Nodules Behave Similarly to Nodules with Benign Cytology

    January 2016
  • Nine New Studies Demonstrate Utility and Long-Term Durability of Afirma GEC (Gene Expression Classifier)

    November 2015
  • Case Study: Genomic Analysis Identifies Medullary Thyroid Carcinoma

    May 2015